Barts & The London NHS Trust
bartshealth.nhs.ukTotal trials
151
Active
24
Phase 3
11
Total enrollment
38,357
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells. | — | — | — | — | — | 1 | |
| Bone marrow derived mononuclear cells and G-CSF | — | — | — | — | — | 1 |
Next readouts
- 2026-08-31
- 2030-03-31
Top conditions
- Atrial Fibrillation16
- Heart Failure6
- Neuropathic Pain5
- Coronary Artery Disease3
- Low Back Pain3
- Marfan Syndrome3
- Marfan Syndrome Cardiovascular Manifestations3
- Hypertrophic Cardiomyopathy3
Frequently asked questions about Barts & The London NHS Trust
- How many clinical trials does Barts & The London NHS Trust have on ClinicalTrials.gov?
- Barts & The London NHS Trust is listed as the lead sponsor on 151 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Barts & The London NHS Trust's trials are in Phase 3?
- 11 of Barts & The London NHS Trust's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Barts & The London NHS Trust focus on?
- Barts & The London NHS Trust's most-studied conditions on ClinicalTrials.gov are Atrial Fibrillation, Heart Failure, Neuropathic Pain, Coronary Artery Disease, Low Back Pain.
- When are Barts & The London NHS Trust's next clinical trial readouts?
- Barts & The London NHS Trust has 2 upcoming primary-completion readouts tracked here; the soonest is “Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina”, expected around 2026-08-31.